Every material Form 8-K iSpecimen Inc. has filed with the SEC since September 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
iSpecimen completed on November 2, 2026, its acquisition of AI software and related assets from Foldlab AI Ltd. for an aggregate price of $4.5 million, paid in cash, milestone payments and stock. The issuance of 2,907,977 shares to Foldlab on November 5, 2026 gives Foldlab approximately 53.6% of the outstanding common stock, a change in control, which means existing shareholders' ownership is substantially diluted.
Purchase price of $4.5 million: $750,000 cash at closing, two $625,000 milestone payments tied to delivery and acceptance, and $2.5 million in stock.
Stock consideration of 2,907,977 shares, based on a $0.8597 volume-weighted average price, issued to Foldlab on November 5, 2026.
Foldlab holds approximately 53.6% of outstanding shares; Zhengkang (Jacob) Shao is its sole director and shareholder.
Shares are subject to a five-year lock-up with no leak-out; stockholders approved the issuance at a special meeting on October 9, 2026.
iSpecimen received a Nasdaq letter dated September 8, 2026, granting an extension until November 25, 2026 to regain compliance with the minimum stockholders' equity requirement. The company says it plans a best-efforts public offering of approximately $5 million in gross proceeds, but the filing states there is no assurance it will regain or maintain compliance, and shareholders could face delisting if it fails to do so.
Nasdaq first notified the company of noncompliance on May 29, 2026, under Listing Rule 5550(b), which requires at least $2,500,000 in stockholders' equity.
The company cites a private placement that closed May 11, 2026, with gross proceeds of approximately $2.5 million, and a planned public offering of approximately $5 million.
Projections show stockholders' equity of approximately $5.1 million through June 30, 2027, per the filing.
The Deficiency Letter has no immediate effect on trading of the common stock on the Nasdaq Capital Market.
iSpecimen agreed to acquire AI software, models, data rights and intellectual property from Foldlab AI Ltd. for $4.5 million, paid $2 million in cash and $2.5 million in common stock. Closing depends on stockholder approval of the share issuance, and the stock would be locked up in escrow for five years, so the deal adds a cash outlay and potential dilution for shareholders.
Purchase price is $4.5 million: $750,000 cash at closing, two $625,000 milestone payments tied to acceptance of each AI product, and $2.5 million in common stock.
Stock consideration is set by dividing $2.5 million by the 10-day VWAP before closing and is subject to a five-year escrow with no leak-out.
Closing requires Buyer Stockholder Approval under Nasdaq Rule 5635(a); either party may terminate if closing has not occurred within 120 days, extendable by up to 60 days.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every iSpecimen Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →